Tao et al. observed that in Kras-mutant NSCLC cells, the inhibition of MEK through trametinib resulted in p16 expression and reduced phosphorylation and therefore activation of the tumorsuppressor RB in the cell line most sensitive toward both sole MEK-inhibition and MEK-inhibition induced radiosensitization. Here, KRAS is linked to non-small cell lung carcinoma.